OBJECTIVE: To determine if the fractional percentage of tumour volume (FPTV) removed at cytoreductive nephrectomy predicts disease-specific survival (DSS), as metastatic renal cell carcinoma ((M+)RCC) is associated with poor overall survival with only a 10-20% patient survival at 2 years. PATIENTS AND METHODS: The Columbia Urologic Oncology Database was reviewed; 1016 patients had renal surgery from 1988 to 2005, 78 patients with (M+)RCC underwent nephrectomy. The FPTV removed was determined using pathological and imaging reports. The patients were stratified as having a > or <90% FPTV. Kaplan-Meier analysis with log-rank test was used to determine survival advantage between groups. A Cox proportional hazard model was used for FPTV in both univariate and multivariate analyses. Secondary analyses were conducted to determine if the size of the primary tumour or volume of metastases affected outcome and if the FPTV affected hospitalization time. RESULTS: In all, 55 patients had their FPTV calculated exactly; 45 had a >90% FPTV. The median DSS times were 11.6 and 2.9 months for patients with >90% and <90% FPTV removed (P = 0.002). The hazard ratio for death was 0.24 for patients with a >90% FPTV in a univariate model (P = 0.016) and 0.29 in multivariate analysis (P = 0.02). Patients with a <90% FPTV spent a greater percentage of time hospitalized before death, 21.2% vs 6.5% (P = 0.03). CONCLUSION: For patients with (M+)RCC, overall survival is limited, but can be extended by cytoreductive nephrectomy. The FPTV expected to be removed is a simple and available method to counsel patients regarding the benefits of surgical intervention.
OBJECTIVE: To determine if the fractional percentage of tumour volume (FPTV) removed at cytoreductive nephrectomy predicts disease-specific survival (DSS), as metastatic renal cell carcinoma ((M+)RCC) is associated with poor overall survival with only a 10-20% patient survival at 2 years. PATIENTS AND METHODS: The Columbia Urologic Oncology Database was reviewed; 1016 patients had renal surgery from 1988 to 2005, 78 patients with (M+)RCC underwent nephrectomy. The FPTV removed was determined using pathological and imaging reports. The patients were stratified as having a > or <90% FPTV. Kaplan-Meier analysis with log-rank test was used to determine survival advantage between groups. A Cox proportional hazard model was used for FPTV in both univariate and multivariate analyses. Secondary analyses were conducted to determine if the size of the primary tumour or volume of metastases affected outcome and if the FPTV affected hospitalization time. RESULTS: In all, 55 patients had their FPTV calculated exactly; 45 had a >90% FPTV. The median DSS times were 11.6 and 2.9 months for patients with >90% and <90% FPTV removed (P = 0.002). The hazard ratio for death was 0.24 for patients with a >90% FPTV in a univariate model (P = 0.016) and 0.29 in multivariate analysis (P = 0.02). Patients with a <90% FPTV spent a greater percentage of time hospitalized before death, 21.2% vs 6.5% (P = 0.03). CONCLUSION: For patients with (M+)RCC, overall survival is limited, but can be extended by cytoreductive nephrectomy. The FPTV expected to be removed is a simple and available method to counsel patients regarding the benefits of surgical intervention.
Authors: Ross J Mason; Lori Wood; Anil Kapoor; Naveen Basappa; George Bjarnason; Stephen A Boorjian; Rodney H Breau; Ilias Cagiannos; Michael A S Jewett; Pierre I Karakiewicz; Wassim Kassouf; Christian Kollmannsberger; Aly-Khan A Lalani; Jean-Baptiste Lattouf; Luke T Lavallée; Stephen Pautler; Nicholas Power; Patrick Richard; Alan So; Simon Tanguay; Ricardo A Rendon Journal: Can Urol Assoc J Date: 2019-06 Impact factor: 1.862
Authors: Vitaly Margulis; Shahrokh F Shariat; Yury Rapoport; Michael Rink; Daniel D Sjoberg; Nizar M Tannir; E Jason Abel; Stephen H Culp; Pheroze Tamboli; Christopher G Wood Journal: Eur Urol Date: 2012-11-23 Impact factor: 20.096
Authors: Renzo G DiNatale; Wanling Xie; Maria F Becerra; Andrew W Silagy; Kyrollis Attalla; Alejandro Sanchez; Roy Mano; Julian Marcon; Kyle A Blum; Nicole E Benfante; Martin H Voss; Robert J Motzer; Jonathan Coleman; Toni K Choueiri; Ed Reznik; Paul Russo; Daniel Y C Heng; A Ari Hakimi Journal: Eur Urol Oncol Date: 2019-11-14
Authors: Axel Bex; Astrid A M van der Veldt; Christian Blank; Alfons J M van den Eertwegh; Epie Boven; Simon Horenblas; John Haanen Journal: World J Urol Date: 2009-01-15 Impact factor: 4.226
Authors: M Neil Reaume; Naveen S Basappa; Lori Wood; Anil Kapoor; Georg A Bjarnason; Normand Blais; Rodney H Breau; Christina Canil; Patrick Cheung; Henry J Conter; Sebastien J Hotte; Claudio Jeldres; Michael A S Jewett; Pierre I Karakiewicz; Christian Kollmannsberger; Francois Patenaude; Alan So; Denis Soulières; Peter Venner; Phillippe Violette; Pawel Zalewski; Heather Chappell; Scott A North Journal: Can Urol Assoc J Date: 2017-10 Impact factor: 1.862